The present invention relates to alkyne compounds of general formula I ##STR00001## wherein the groups and residues A, B, W, X, Y, Z, R.sup.1 and R.sup.2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.